Epoxia offers an advancement in corneal cross-linking for the treatment of keratoconus. Glaukos describes the rare, sight-threatening disease as “currently far too often undiagnosed and untreated.”

Aliso Viejo, California-based Glaukos developed Epoxia to eliminate the need for the removal of the corneal epithelium — the eye’s outermost layer. The novel, oxygen-enriched topical therapeutic is activated by UV light, designed to eliminate the pain associated with epithelium removal. It also streamlines procedures and minimizes recovery time.

Glaukos offers Epoxia based on two formulations, Epoxia HD and Epoxia. Sequentially administered during the cross-linking procedure, these formulations are followed by UV activation in an oxygen-enriched environment.